The Approaches to Schizophrenia Communication (ASC) Tool: Including the Patient Perspective in Treatment

Disease Management and Health Outcomes

Volumn 11, Issue 11, 2003, Pages 699-708

  Dassori, Albana M ^a,b   Miller, Alexander L ^a,b   Weiden, Peter J ^c  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b San Antonio State Hospital   (United States)

^c SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZATROPINE; BIPERIDEN; NEUROLEPTIC AGENT;

AKATHISIA; AKINESIA; AMENORRHEA; ANTICHOLINERGIC EFFECT; CLINICAL PRACTICE; CONSTIPATION; DISEASE SEVERITY; DOCTOR PATIENT RELATION; DYSKINESIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; GALACTORRHEA; GYNECOMASTIA; HUMAN; HYPERKINESIA; HYPOKINESIA; INSOMNIA; INTERPERSONAL COMMUNICATION; MEDICAL SOCIETY; MICTURITION DISORDER; MUSCLE RIGIDITY; NEUROLEPTIC MALIGNANT SYNDROME; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PSYCHIATRIST; QUALITY OF LIFE; QUESTIONNAIRE; RESTLESSNESS; REVIEW; SCHIZOPHRENIA; SEDATION; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; TARDIVE DYSKINESIA; TREMOR; URINE RETENTION; VISUAL IMPAIRMENT; WEIGHT GAIN; XEROSTOMIA;

EID: 0242361107     PISSN: 11738790     EISSN: None     Source Type: Journal    
DOI: 10.2165/00115677-200311110-00002     Document Type: Review

References (24)

1. Charles C, Gafni A, Whelan T. Shared decision-making in the medical encounter: what does it mean? (or it takes at least two to tango). Soc Sci Med 1997 Mar; 44 (5): 681-92
2. Stevenson FA, Barry CA, Britten N, et al. Doctor-patient communication about drugs: the evidence for shared decision making. Soc Sci Med 2000 Mar; 50 (6): 829-40
3. Frosch DL, Kaplan RM. Shared decision making in clinical medicine: past research and future directions. Am J Prev Med 1999 Nov; 17 (4): 285-94
4. Weiden P, Miller AL. Which side effects really matter? Screening for common and distressing side effects of antipsychotic medications. J Psychiatr Pract 2001; 7: 41-7
5. Hellewell JSE. Patients' subjective experiences of antipsychotics: clinical relevance. CNS Drugs 2002; 16 (7): 457-71
6. Awad AG, Hogan TP. Early treatment events and prediction of response to neuroleptics in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 1985; 9 (5-6): 585-8
7. Awad AG, Voruganti LN, Heslegrave RJ, et al. Assessment of the patient's subjective experience in acute neuroleptic treatment: implications for compliance and outcome. Int Clin Psychopharmacol 1996 May; 11 (2 Suppl.): 55-9
8. Van Putten T, May PR. Subjective response as a predictor of outcome in pharmacotherapy: the consumer has a point. Arch Gen Psychiatry 1978 Apr; 35 (4): 477-80
9. Awad AG, Hogan TP, Voruganti LN, et al. Patients' subjective experiences on antipsychotic medications: implications for outcome and quality of life. Int Clin Psychopharmacol 1995; 10 (3 Suppl.): 123-32
10. Awad AG, Voruganti LNP, Heslegrave RJ. A conceptual model of quality of life in schizophrenia: description and preliminary clinical validation. Qual Life Res 1997; 6 (1): 21-6
11. Voruganti LNP, Heslegrave RJ, Awad AG. Neuroleptic dysphoria may be the missing link between schizophrenia and substance abuse. J Nerv Ment Dis 1997; 185 (7): 463-5
12. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983; 13 (1): 177-83
13. Van Putten T, May PR, Marder SR, et al. Subjective response to antipsychotic drugs. Arch Gen Psychiatry 1981 Feb; 38 (2): 187-90
14. Naber D, Walther A, Kirshere T, et al. Subjective effects of neuroleptics predict compliance. In: Gaebel W, Awad AG, editors. Prediction of neuroleptic treatment outcome in schizophrenia: concepts and methods. Vienna: Springer-Verlag, 1994: 469-73
15. Adams S, Howe J. Predicting medication compliance in a psychotic population. J Nerv Ment Dis 1993; 181: 558-60
16. Buchanan A. A two-year prospective study of treatment compliance in patients with schizophrenia. Psychol Med 1992 Aug; 22 (3): 787-97
17. Weiden P, Rapkin B, Mott T, et al. Rating of medication influences (ROMI) scale in schizophrenia. Schizophr Bull 1994; 20 (2): 297-310
18. Dott SG, Weiden P, Hopwood P, et al. An innovative approach to clinical communication in schizophrenia: the approaches to schizophrenia communication checklists. CNS Spectrums 2001; 6: 333-8
19. Hellewell JSE. Do we know what matters to our patients? Clear Perspectives: Manage Issues Schizophr 1999; 2: 1-4
20. Young AS, Sullivan G, Burnam MA, et al. Measuring the quality of outpatient treatment for schizophrenia. Arch Gen Psychiatry 1998; 55: 611-7
21. Larsen EB, Gerlach J. Subjective experience of treatment, side-effects, mental state and quality of life in chronic schizophrenic out-patients treated with depot neuroleptics. Acta Psychiatr Scand 1996; 93 (5): 381-8
22. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 1987; (334 Suppl.): 1-100
23. Chaudhry IB, Soni SD. ACS in clinical practice: the UK experience. Clear Perspectives: Manage Issues Schizophr 1999; 2: 22-4
24. Miller AL, Dassori AM. ASC in US clinical practice. Clear Perspectives: Manage Issues Schizophr 1999; 2 (4): 20-1